Table 1.
Patient characteristics
| Characteristic | Value |
|---|---|
| Number of patients | 11 |
| Median age, y (range) | 64 (41-75) |
| Disease | |
| DLBCL | 9/11 |
| MCL | 2/11 |
| CAR T cells | |
| Axi-cel | 9/11 |
| Brexu-cel | 2/11 |
| Median CAR-HEMATOTOX score (range) | 3 (0-5) |
| Type of TPO-RA | |
| Eltrombopag | 10/11 |
| Romiplostim | 1/11 |
| Median follow-up from CAR T-cell infusion, d (range) | 274 (90-828) |
| Median platelets count at 1 mo of TPO-RA initiation, ×109/L (range) | 28 (13-295) |
| Median platelets count at 2 mo of TPO-RA initiation, ×109/L (range) | 60 (8-226) |
| Median platelets count at 3 mo of TPO-RA initiation, ×109/L (range) | 68 (17-162) |
| Median time between CAR T-cell infusion and start of TPO-RA, d (range) | 27 (14-45) |
| Median duration of TPO-RA, d (range) | 97 (27-180) |
| Number of patients free of platelet transfusion after TPO-RA | 10/11∗ |
| Median duration between start of TPO-RA and last transfusion, d (range)† | 17 (1-65) |
| Median duration between start of TPO-RA and platelet recovery, d (range)† | 46 (18-100) |
| Median duration between CAR T-cell infusion and last transfusion, d (range)† | 46 (21-104) |
| Median duration between CAR T-cell infusion and platelet recovery, d (range)† | 76 (53-130) |
Brexu-cel, brexucabtagene-autoleucel; MCL, mantle cell lymphoma.
∗
Patient 2 was still undergoing transfusion at 6 mo after CAR T-cell infusion.
†
Patient 2 excluded, because still undergoing transfusion at 6 mo after CAR T-cell infusion. Platelet recovery was defined as 2 consecutive platelet counts >50 × 109/L.